超预期:实施后数据显示澳大利亚轮状病毒疫苗接种可能节约成本
澳大利亚2007年7月将轮状病毒疫苗纳入国家免疫规划,本研究利用实施后全国数据进行回顾性经济评价,采用多队列区室模型从医疗付费方视角分析。结果显示2007至2012年6年间估计避免约77,000例住院和约3例死亡,同时估计超额肠套叠78例;当将轮状病毒编码及未特指急性胃肠炎住院下降均归因于疫苗时,项目节约成本,获益远大于肠套叠风险。
要点
- 2007至2012年估计避免约77,000例住院(轮状病毒编码17,000例、未特指急性胃肠炎60,000例)和约3例死亡。
- 估计超额肠套叠78例,其不良影响远小于项目获益。
- 约90%避免的住院发生在5岁以下儿童,并观察到较大年龄组群体保护证据。
核心结论
- 纳入群体效应和未特指急性胃肠炎住院下降后,澳大利亚轮状病毒免疫规划的成本效益远高于实施前模型预测,尽管可能存在肠套叠病例增加。
- 澳大利亚经验可能对尚未实施轮状病毒疫苗接种规划的高收入国家有参考意义。
研究设计与样本
- 对澳大利亚轮状病毒规划进行回顾性经济评价,使用全国层面实施后疫苗 uptake、项目实施前后影响指标及已发表的超额肠套叠病例估计。
- 上述数据作为输入纳入多队列区室模型,将成本和生命质量估计分配至相关健康状态,采用医疗付费方视角。
- 主要结局为每获得一个质量调整生命年的贴现成本,分别包括或排除未特指急性胃肠炎住院。
主要发现
- 相对于基线期(1997-2006年),实施后6年(2007-2012年)估计避免约77,000例住院(轮状病毒编码17,000例和未特指急性胃肠炎60,000例)和约3例死亡,同时估计超额肠套叠78例。
- 约90%避免的住院发生在5岁以下儿童,并有较大年龄组群体保护证据。
- 当观察到的轮状病毒编码住院和未特指急性胃肠炎住院下降均归因于轮状病毒疫苗规划时,该规划节约成本。
- 估计超额肠套叠病例的不良影响远小于该规划的获益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Universal vaccination against rotavirus was included in the funded Australian National Immunisation Program in July 2007. Predictive cost-effectiveness models assessed the program before introduction. METHODS: We conducted a retrospective economic evaluation of the Australian rotavirus program using national level post-implementation data on vaccine uptake, before-after measures of program impact and published estimates of excess intussusception cases. These data were used as inputs into a multi-cohort compartmental model which assigned cost and quality of life estimates to relevant health states, adopting a healthcare payer perspective. The primary outcome was discounted cost per quality adjusted life year gained, including or excluding unspecified acute gastroenteritis (AGE) hospitalisations. RESULTS: Relative to the baseline period (1997-2006), over the 6years (2007-2012) after implementation of the rotavirus program, we estimated that ∼77,000 hospitalisations (17,000 coded rotavirus and 60,000 unspecified AGE) and ∼3 deaths were prevented, compared with an estimated excess of 78 cases of intussusception. Approximately 90% of hospitalisations prevented were in children <5years, with evidence of herd protection in older age groups. The program was cost-saving when observed changes (declines) in both hospitalisations coded as rotavirus and as unspecified AGE were attributed to the rotavirus vaccine program. The adverse impact of estimated excess cases of intussusception was far outweighed by the benefits of the program. CONCLUSION: The inclusion of herd impact and declines in unspecified AGE hospitalisations resulted in the value for money achieved by the Australian rotavirus immunisation program being substantially greater than predicted bypre-implementation models, despite the potential increased cases of intussusception. This Australian experience is likely to be relevant to high-income countries yet to implement rotavirus vaccination programs.
引用
- Reyes JF, Wood JG, Beutels P, et al. Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia. Vaccine. 2017. PMID: 27916411. doi:10.1016/j.vaccine.2016.11.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。